skip to the main content

Cyfra21-1

Supporting to diagnose Non-Small-Cell Lung Cancer (NSCLC)

Cyfra21-1 belongs to a cytokeratin family, which is normally expressed in epithelial tissues and forms the epithelial cells’ filament cytoskeleton and it can be used as a circulating tumor marker. Although expressed in all body tissues, its major occurrence is in the lung, particularly in lung cancer tissues, so it is a sensitive, specific, and valuable biomarker for estimation of diagnosis, prognosis, and therapy monitoring of non-small-cell lung cancer (NSCLC), especially of squamous cell subtype.

Diagnosis diseases
Lung Cancer
  • CE 0123

About Using Reagent

  • Sample Types

    Serum, Plasma
  • Reaction Time

    12 mins
  • Detection Range

    1-500 ng/mL
  • Intended Use

    Quantitative determination of Cyfra21-1 in human serum/plasma.

In Your Medical Field

Lung cancer is the No.1 most common cancer in the world. It is by far the leading cause of cancer death, making up almost 25% of all cancer deaths. If lung cancer is detected at an early stage, the 5-year survival rate is more than 80%, so early detection and diagnosis is urgent for the sake of an effective treatment strategy for lung cancer. Cyfra21-1 is useful for detecting disease relapse, assessing surgical chemotherapeutic efficacy, predicting very advanced cases and overall prognosis of lung cancer.

Our Efforts to be with you